These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 34245387)

  • 21. A tetravalent dengue vaccine containing a mix of domain III-P64k and domain III-capsid proteins induces a protective response in mice.
    Izquierdo A; García A; Lazo L; Gil L; Marcos E; Alvarez M; Valdés I; Hermida L; Guillén G; Guzmán MG
    Arch Virol; 2014 Oct; 159(10):2597-604. PubMed ID: 24841761
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A novel dengue vaccine candidate that induces cross-neutralizing antibodies and memory immunity.
    Leng CH; Liu SJ; Tsai JP; Li YS; Chen MY; Liu HH; Lien SP; Yueh A; Hsiao KN; Lai LW; Liu FC; Chong P; Chen HW
    Microbes Infect; 2009 Feb; 11(2):288-95. PubMed ID: 19114121
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunological evaluation in nonhuman primates of formulations based on the chimeric protein P64k-domain III of dengue 2 and two components of Neisseria meningitidis.
    Valdés I; Hermida L; Martín J; Menéndez T; Gil L; Lazo L; Castro J; Niebla O; López C; Bernardo L; Sánchez J; Romero Y; Martínez R; Guzmán MG; Guillén G
    Vaccine; 2009 Feb; 27(7):995-1001. PubMed ID: 19100804
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunogenicity of a novel tetravalent vaccine formulation with four recombinant lipidated dengue envelope protein domain IIIs in mice.
    Chiang CY; Pan CH; Chen MY; Hsieh CH; Tsai JP; Liu HH; Liu SJ; Chong P; Leng CH; Chen HW
    Sci Rep; 2016 Jul; 6():30648. PubMed ID: 27470096
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Construction of sub-unit dengue vaccines and analysis of its immunogenicity].
    Zhang ZS; Yan YS; Weng YW
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2010 Dec; 24(6):430-2. PubMed ID: 21604567
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Production in yeast of pseudotype virus-like particles harboring functionally active antibody fragments neutralizing the cytolytic activity of vaginolysin.
    Pleckaityte M; Zvirbliene A; Sezaite I; Gedvilaite A
    Microb Cell Fact; 2011 Dec; 10():109. PubMed ID: 22171920
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ebolavirus Glycoprotein Fc Fusion Protein Protects Guinea Pigs against Lethal Challenge.
    Konduru K; Shurtleff AC; Bradfute SB; Nakamura S; Bavari S; Kaplan G
    PLoS One; 2016; 11(9):e0162446. PubMed ID: 27622456
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Molecular engineering and plant expression of an immunoglobulin heavy chain scaffold for delivery of a dengue vaccine candidate.
    Kim MY; Van Dolleweerd C; Copland A; Paul MJ; Hofmann S; Webster GR; Julik E; Ceballos-Olvera I; Reyes-Del Valle J; Yang MS; Jang YS; Reljic R; Ma JK
    Plant Biotechnol J; 2017 Dec; 15(12):1590-1601. PubMed ID: 28421694
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Targeting of envelope domain III protein of DENV type 2 to DEC-205 receptor elicits neutralizing antibodies in mice.
    Coconi-Linares N; Ortega-Dávila E; López-González M; García-Machorro J; García-Cordero J; Steinman RM; Cedillo-Barrón L; Gómez-Lim MA
    Vaccine; 2013 May; 31(19):2366-71. PubMed ID: 23499580
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of tetravalent and conserved synthetic peptides vaccines derived from Dengue virus Envelope domain I and II.
    Rocha RP; Livonesi MC; Fumagalli MJ; Rodrigues NF; da Costa LC; Dos Santos MC; de Oliveira Rocha ES; Kroon EG; Malaquias LC; Coelho LF
    Virus Res; 2014 Aug; 188():122-7. PubMed ID: 24768848
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dendritic Cell Targeting Using a DNA Vaccine Induces Specific Antibodies and CD4
    Zaneti AB; Yamamoto MM; Sulczewski FB; Almeida BDS; Souza HFS; Ferreira NS; Maeda DLNF; Sales NS; Rosa DS; Ferreira LCS; Boscardin SB
    Front Immunol; 2019; 10():59. PubMed ID: 30761131
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safe Staphylococcal Platform for the Development of Multivalent Nanoscale Vesicles against Viral Infections.
    Yuan J; Yang J; Hu Z; Yang Y; Shang W; Hu Q; Zheng Y; Peng H; Zhang X; Cai X; Zhu J; Li M; Hu X; Zhou R; Rao X
    Nano Lett; 2018 Feb; 18(2):725-733. PubMed ID: 29253342
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dengue-1 envelope protein domain III produced in Pichia pastoris: potential use for serological diagnosis.
    Cardoso SA; Paixão VF; Oliveira MD; Honda ER; Oliveira LL; da Silva CC; De Paula SO
    Protein Expr Purif; 2013 Nov; 92(1):9-13. PubMed ID: 23993978
    [TBL] [Abstract][Full Text] [Related]  

  • 34. An Envelope-Modified Tetravalent Dengue Virus-Like-Particle Vaccine Has Implications for Flavivirus Vaccine Design.
    Urakami A; Ngwe Tun MM; Moi ML; Sakurai A; Ishikawa M; Kuno S; Ueno R; Morita K; Akahata W
    J Virol; 2017 Dec; 91(23):. PubMed ID: 28956764
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Expression and purification of domain III proteins from Dengue and Zika viruses.
    Corzo-Gómez J; García-Cordero J; Montes Gómez AE; Bernal-Siria K; Namorado-Tónix K; Gutierrez-Castañeda B; Cedillo-Barrón L
    Protein Expr Purif; 2019 Oct; 162():38-43. PubMed ID: 31112759
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Purified and highly aggregated chimeric protein DIIIC-2 induces a functional immune response in mice against dengue 2 virus.
    Marcos E; Gil L; Lazo L; Izquierdo A; Brown E; Suzarte E; Valdés I; García A; Méndez L; Guzmán MG; Guillén G; Hermida L
    Arch Virol; 2013 Jan; 158(1):225-30. PubMed ID: 22983185
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Production of dengue virus envelope protein domain III-based antigens in tobacco chloroplasts using inducible and constitutive expression systems.
    Gottschamel J; Lössl A; Ruf S; Wang Y; Skaugen M; Bock R; Clarke JL
    Plant Mol Biol; 2016 Jul; 91(4-5):497-512. PubMed ID: 27116001
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dengue and Zika Virus Domain III-Flagellin Fusion and Glycan-Masking E Antigen for Prime-Boost Immunization.
    Lin HH; Yang SP; Tsai MJ; Lin GC; Wu HC; Wu SC
    Theranostics; 2019; 9(16):4811-4826. PubMed ID: 31367259
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tests in mice of a dengue vaccine candidate made of chimeric Junin virus-like particles and conserved dengue virus envelope sequences.
    Mareze VA; Borio CS; Bilen MF; Fleith R; Mirazo S; Mansur DS; Arbiza J; Lozano ME; Bruña-Romero O
    Appl Microbiol Biotechnol; 2016 Jan; 100(1):125-33. PubMed ID: 26386688
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A recombinant fusion protein containing the domain III of the dengue-2 envelope protein is immunogenic and protective in nonhuman primates.
    Hermida L; Bernardo L; Martín J; Alvarez M; Prado I; López C; Sierra Bde L; Martínez R; Rodríguez R; Zulueta A; Pérez AB; Lazo L; Rosario D; Guillén G; Guzmán MG
    Vaccine; 2006 Apr; 24(16):3165-71. PubMed ID: 16490289
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.